Watching, Delaying Treatment Of Low-Risk Prostate Cancer May Be More Cost-Effective Approach

Bottom Line: Active surveillance of men with low-risk prostate cancer may be better for quality of life and is cost-effective compared with immediate treatment, reports a study published today in CMAJ Open. Prostate Cancer: Prostate cancer is the most common cancer in Canadian men and the third leading cause of death from cancer. The incidence of … Continue reading Watching, Delaying Treatment Of Low-Risk Prostate Cancer May Be More Cost-Effective Approach

Medication Does Not Help Prevent Erectile Dysfunction Following Radiation Therapy for Prostate Cancer

Bottom Line: Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA. Background: Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer treatment. An … Continue reading Medication Does Not Help Prevent Erectile Dysfunction Following Radiation Therapy for Prostate Cancer

Metabolic Factors May Up Men’s Risk of Dying From Prostate Cancer

Risk of death in men suffering from prostate cancer could be increased by metabolic factors according to the latest research published in the journal of Cancer, a peer-reviewed journal of the American Cancer Society. Certain common symptoms of metabolic syndrome alter blood sugar, blood pressure, body mass index and blood lipids.

Aggressive Prostate Cancer May Be Detected By Barcode Blood Test

Most aggressive type of prostate cancer can be detected by using barcode blood test as shown by latest research published in the Lancet Oncology journal. This test could select which patients of prostate cancer require immediate treatment by determining the pattern of genes switched on and switched off in blood samples as suggested by staff … Continue reading Aggressive Prostate Cancer May Be Detected By Barcode Blood Test

Survival Rate Could be Increased with Enzalutamide in Prostate Cancer Patients After Chemotherapy

Latest research which was published in New England Journal of Medicine (NEJM) has shown that survival of prostate cancer patients could be increased by using Enzalutamide. It has been estimated that 241,740 men will suffer and 28,170 men will be died due to prostate cancer in 2012.